Products

All forms of Parkinson's disease: idiopathic (paralysis agitans), postencephalitic and arteriosclerotic. Symptoms often responding well to Kemadrin include rigidity, akinesia, tremor, speech and writing difficulties, gait, sialorrhoea and drooling, sweating, oculogyric crises and depressed mood.

Kemadrin is also used to control troublesome extrapyramidal symptoms induced by neuroleptic drugs including pseudoparkinsonism, acute dystonic reactions and akathisia.

Intra-Articular: Kenacort-A 10 Injection (Sterile Triamcinolone Acetonide Suspension USP) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, post-traumatic osteoarthritis. Intradermal: Intralesional administration of Kenacort-A 10 Injection is indicated for the treatment of keloids, discoid lupus erythematous, necrobiosis lipoidica diabeticorum, alopecia areata and localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis), Kenacort-A 10 Injection also may be useful in cystic tumours of an aponeurosis or tendon (ganglia).

Intramuscular: The intramuscular administration of Kenacort-A 40 (Sterile Triamcinolone Acetonide Suspension USP) is indicated for systemic corticosteroid therapy in such conditions as allergic diseases, dermatoses, or generalised rheumatoid arthritis and other connective tissue disorders. Intramuscular administration is particularly valuable in such conditions when oral corticosteroid therapy is not feasible. Intra-Articular: Kenacort-A 40 Injection (Sterile Triamcinolone Acetonide Suspension USP) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in; synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute nonspecific tenosynovitis; post-traumatic osteoarthritis.

Acute and chronic lesions of the oral mucosa including recurrent ulcerative aphthous stomatitis; Erosive lichen planus; denture stomatitis; traumatic lesions including denture sore spots; desquamative gingivitis and stomatitis. Lesions of traumatic origin and most nonrecurring conditions heal rapidly and permanently. Chronic and recurrent lesions are promptly relieved, but symptoms usually recur after termination of therapy. However, Kenalog in Orabase is effective in suppressing subsequent recurrences.